New location in Hamburg underpins growth plans
With a new location in Hamburg (since January 2021), flatexDEGIRO underpins its growth plans and strengthens especially the product management, marketing and banking center with highly experienced retail online brokerage experts.
-
DEGIRO repeatedly named best broker in Spain
For the fifth time in a row, DEGIRO was awarded Best Stock Broker 2020 as well as Best Multi-Product Broker 2020 in Spain. Our outstanding development and rapid growth in Spain are the logical consequence of this continuous, exceptional customer satisfaction.
-
Germany s largest ETF and fund savings plan offering, permanently at zero cost
Since 1 April 2021, flatex has been offering its entire ETF and fund savings plan range in Germany, with over 3,000 products, permanently free of charge. In addition, the custody account fee for all ETF and fund products will be waived from now on. New and existing customers alike benefit from this offer, which is uniq
Nachricht vom 08.04.2021 | 06:59
flatexDEGIRO delivers excellent business development in the strongest growth year in history (news with additional features)
DGAP-News: flatexDEGIRO AG / Key word(s): Annual Report/Annual Results
08.04.2021 / 06:59
flatexDEGIRO delivers excellent business development in the strongest growth year in history
- Full confirmation of the preliminary figures published in February for revenues (EUR 261.5 m), adjusted EBITDA (EUR 114.0 m), and operating cash flow (EUR 141.5 m)
- Great financial strength driven by high operating cash flow and no financial debt
- Very solid equity position increases further to EUR 446 m (+145 %)
- Convincing product and price offering on one of the most stable and secure platforms generates continuous high customer inflow
About Silence Therapeutics plc Silence Therapeutics is developing a new generation of medicines by harnessing the body s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of comp
Message :
Required fields DGAP-News: flatexDEGIRO AG / Key word(s): Interim Report/Forecast
flatexDEGIRO AG ends record year beating management guidance
2021-01-11 / 07:00
The issuer is solely responsible for the content of this announcement.
Corporate News / Frankfurt/Main, 11 January 2021
flatexDEGIRO AG ends record year beating management guidance
? flatexDEGIRO leads European retail online brokerage market with 75m
settled transactions (pro forma) in 2020 (+140% versus 2019)
? Customer base grown by over 50% to 1.25m (2019: 0.80 m, pro forma)
? Expectation 2021: over 1.6m customers, 65-75m transactions
? flatexDEGIRO full steam ahead on the way to deliver Vision 2025
Frankfurt/Main - flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker:
FTK.GR), Europe s largest retail online broker, continues its strong growth
Share:
ENDEAVOUR AND TERANGA ANNOUNCE RECEIPT OF INTERIM COURT ORDER AND MAILING OF JOINT INFORMATION CIRCULAR
George Town & Toronto, December 21, 2020 – Endeavour Mining Corporation (TSX:EDV) (OTCQX:EDVMF) ( Endeavour ) and Teranga Gold Corporation (TSX:TGZ) (OTCQX:TGCDF) ( Teranga ) are pleased to announce that they have filed the joint management information circular (the Circular ) in connection with the extraordinary general and special meetings of Endeavour and Teranga, each scheduled to be held on January 21, 2021 (the Meetings ). The purpose of the Meetings is to seek approval for the proposed acquisition by Endeavour of all the issued and outstanding securities of Teranga by way of a plan of arrangement under the